Volume 184, Issue 3 pp. 675-693
RESEARCH ARTICLE
Open Access

RP2-associated retinal disorder in a Japanese cohort: Report of novel variants and a literature review, identifying a genotype–phenotype association

Kaoru Fujinami

Corresponding Author

Kaoru Fujinami

Laboratory of Visual Physiology, Division of Vision Research, National Institute of Sensory Organs, National Hospital Organization Tokyo Medical Center, Tokyo, Japan

Department of Ophthalmology, Keio University School of Medicine, Tokyo, Japan

UCL Institute of Ophthalmology, London, UK

Moorfields Eye Hospital, London, UK

Correspondence

Kaoru Fujinami, Laboratory of Visual Physiology, Division for Vision Research, National Institute of Sensory Organs, National Hospital Organization Tokyo Medical Center, No. 2-5-1, Higashigaoka, Meguro-ku, Tokyo 152-8902 Japan.

Email: [email protected]

Search for more papers by this author
Xiao Liu

Xiao Liu

Laboratory of Visual Physiology, Division of Vision Research, National Institute of Sensory Organs, National Hospital Organization Tokyo Medical Center, Tokyo, Japan

Department of Ophthalmology, Keio University School of Medicine, Tokyo, Japan

Southwest Hospital/Southwest Eye Hospital, Third Military Medical University (Army Medical University), Chongqing, China

Search for more papers by this author
Shinji Ueno

Shinji Ueno

Department of Ophthalmology, Nagoya University Graduate School of Medicine, Nagoya, Japan

Search for more papers by this author
Atsushi Mizota

Atsushi Mizota

Department of Ophthalmology, Teikyo University, Tokyo, Japan

Search for more papers by this author
Kei Shinoda

Kei Shinoda

Department of Ophthalmology, Teikyo University, Tokyo, Japan

Department of Ophthalmology, Saitama Medical University, Moroyama Campus, Saitama, Japan

Search for more papers by this author
Kazuki Kuniyoshi

Kazuki Kuniyoshi

Department of Ophthalmology, Kindai University Faculty of Medicine, Osaka-Sayama, Japan

Search for more papers by this author
Yu Fujinami-Yokokawa

Yu Fujinami-Yokokawa

Laboratory of Visual Physiology, Division of Vision Research, National Institute of Sensory Organs, National Hospital Organization Tokyo Medical Center, Tokyo, Japan

UCL Institute of Ophthalmology, London, UK

Department of Health Policy and Management, Keio University School of Medicine, Tokyo, Japan

Division of Public Health, Yokokawa Clinic, Suita, Japan

Search for more papers by this author
Lizhu Yang

Lizhu Yang

Laboratory of Visual Physiology, Division of Vision Research, National Institute of Sensory Organs, National Hospital Organization Tokyo Medical Center, Tokyo, Japan

Department of Ophthalmology, Keio University School of Medicine, Tokyo, Japan

Search for more papers by this author
Gavin Arno

Gavin Arno

Laboratory of Visual Physiology, Division of Vision Research, National Institute of Sensory Organs, National Hospital Organization Tokyo Medical Center, Tokyo, Japan

UCL Institute of Ophthalmology, London, UK

Moorfields Eye Hospital, London, UK

North East Thames Regional Genetics Service, UCL Great Ormond Street Institute of Child Health, NHS Foundation Trust, London, UK

Search for more papers by this author
Nikolas Pontikos

Nikolas Pontikos

Laboratory of Visual Physiology, Division of Vision Research, National Institute of Sensory Organs, National Hospital Organization Tokyo Medical Center, Tokyo, Japan

UCL Institute of Ophthalmology, London, UK

Moorfields Eye Hospital, London, UK

Search for more papers by this author
Shuhei Kameya

Shuhei Kameya

Department of Ophthalmology, Nippon Medical School Chiba Hokusoh Hospital, Inzai, Japan

Search for more papers by this author
Taro Kominami

Taro Kominami

Department of Ophthalmology, Nagoya University Graduate School of Medicine, Nagoya, Japan

Search for more papers by this author
Hiroko Terasaki

Hiroko Terasaki

Department of Ophthalmology, Nagoya University Graduate School of Medicine, Nagoya, Japan

Search for more papers by this author
Hiroyuki Sakuramoto

Hiroyuki Sakuramoto

Department of Ophthalmology, Kindai University Faculty of Medicine, Osaka-Sayama, Japan

Search for more papers by this author
Natsuko Nakamura

Natsuko Nakamura

Laboratory of Visual Physiology, Division of Vision Research, National Institute of Sensory Organs, National Hospital Organization Tokyo Medical Center, Tokyo, Japan

Department of Ophthalmology, Teikyo University, Tokyo, Japan

Department of Ophthalmology, The University of Tokyo, Tokyo, Japan

Search for more papers by this author
Toshihide Kurihara

Toshihide Kurihara

Department of Ophthalmology, Keio University School of Medicine, Tokyo, Japan

Search for more papers by this author
Kazuo Tsubota

Kazuo Tsubota

Department of Ophthalmology, Keio University School of Medicine, Tokyo, Japan

Search for more papers by this author
Yozo Miyake

Yozo Miyake

Laboratory of Visual Physiology, Division of Vision Research, National Institute of Sensory Organs, National Hospital Organization Tokyo Medical Center, Tokyo, Japan

Aichi Medical University, Nagakute, Japan

Next vision, Kobe Eye Center, Kobe, Japan

Search for more papers by this author
Kazutoshi Yoshiake

Kazutoshi Yoshiake

Division of Molecular and Cellular Biology, National Institute of Sensory Organs, National Hospital Organization Tokyo Medical Center, Tokyo, Japan

Search for more papers by this author
Takeshi Iwata

Takeshi Iwata

Division of Molecular and Cellular Biology, National Institute of Sensory Organs, National Hospital Organization Tokyo Medical Center, Tokyo, Japan

Search for more papers by this author
Kazushige Tsunoda

Kazushige Tsunoda

Laboratory of Visual Physiology, Division of Vision Research, National Institute of Sensory Organs, National Hospital Organization Tokyo Medical Center, Tokyo, Japan

Search for more papers by this author
Japan Eye Genetics Consortium Study Group

Japan Eye Genetics Consortium Study Group

Search for more papers by this author
First published: 01 September 2020
Citations: 5

Kaoru Fujinami and Xiao Liu are joint first authors of this study.

Funding information: FOUNDATION FIGHTING BLINDNESS ALAN LATIES CAREER DEVELOPMENT PROGRAM, Grant/Award Number: CF-CL-0416-0696-UCL; Grant-in-Aid for Scientists to support international collaborative studies of the Ministry of Education, Culture, Sports, Science and Technology, Japan, Grant/Award Number: 16KK01930002; Grant-in-Aid for Young Scientists (A) of the Ministry of Education, Culture, Sports, Science and Technology, Japan, Grant/Award Number: 16H06269; Great Britain Sasakawa Foundation Butterfield Awards; Health Labour Sciences Research Grant, The Ministry of Health Labour and Welfare, Grant/Award Number: 201711107A; National Hospital Organization Network Research Fund, Grant/Award Number: H30-NHO-Sensory Organs-03; Novartis Research Grant; Grants-in-Aid for Scientific Research, Japan Society for the Promotion of Science, Japan, Grant/Award Number: H26-26462674; Ministry of Health, Labor and Welfare, Grant/Award Number: 18ek0109282h0002; Japan Agency for Medical Research and Development (AMED); ROHTO Pharmaceutical Co., Ltd.; Santen Pharmaceutical Co. Ltd.; Novartis Pharmaceuticals; Kowa Company, Ltd.; Kirin Company, Ltd.; Fuji Xerox Co., Ltd.; Tsubota Laboratory, Inc.; UCL Institute of Ophthalmology; Great Britain Sasakawa Foundation Butterfield Award; UCL Institute of Child Health; Great Ormond Street Hospital; Moorfields Eye Hospital; Ministry of Education, Culture, Sports, Science and Technology, Grant/Award Number: 18K16943

Abstract

The retinitis pigmentosa 2 (RP2) gene is one of the causative genes for X-linked inherited retinal disorder. We characterized the clinical/genetic features of four patients with RP2-associated retinal disorder (RP2-RD) from four Japanese families in a nationwide cohort. A systematic review of RP2-RD in the Japanese population was also performed. All four patients were clinically diagnosed with retinitis pigmentosa (RP). The mean age at examination was 36.5 (10–47) years, and the mean visual acuity in the right/left eye was 1.40 (0.52–2.0)/1.10 (0.52–1.7) in the logarithm of the minimum angle of resolution unit, respectively. Three patients showed extensive retinal atrophy with macular involvement, and one had central retinal atrophy. Four RP2 variants were identified, including two novel missense (p.Ser6Phe, p.Leu189Pro) and two previously reported truncating variants (p.Arg120Ter, p.Glu269CysfsTer3). The phenotypes of two patients with truncating variants were more severe than the phenotypes of two patients with missense variants. A systematic review revealed additional 11 variants, including three missense and eight deleterious (null) variants, and a statistically significant association between phenotype severity and genotype severity was revealed. The clinical and genetic spectrum of RP2-RD was illustrated in the Japanese population, identifying the characteristic features of a severe form of RP with early macular involvement.

CONFLICT OF INTEREST

All authors have completed and submitted the ICMJE Form for disclosure of potential conflicts of interest. Individual investigators who participate in the sponsored project(s) are not directly compensated by the sponsor but may receive a salary or other support from the institution to support their effort on the project(s).

Kaoru Fujinami is a paid Consultant for Astellas Pharma Inc., Kubota Pharmaceutical Holdings Co., Ltd., Acucela Inc., Novartis AG, Janssen Pharmaceutica, Sanofi Genzyme, NightstaRx Limited; reports personal fees from Astellas Pharma Inc., Kubota Pharmaceutical Holdings Co., Ltd., Acucela Inc., Novartis AG, Santen Company Limited, Foundation Fighting Blindness, Foundation Fighting Blindness Clinical Research Institute, Japanese Ophthalmology Society, Japan Retinitis Pigmentosa Society; reports grants from Astellas Pharma Inc. (NCT03281005), outside the submitted work.

Toshihide Kurihara is an investor in Tsubota Laboratory, Inc. and RestoreVision, Inc. Toshihide Kurihara reports grants and personal fees from ROHTO Pharmaceutical Co., Ltd., Tsubota Laboratory, Inc., Fuji Xerox Co., Ltd., Kowa Company, Ltd., Santen Pharmaceutical Co. Ltd., outside the submitted work.

Kazuo Tsubota reports grants and personal fees from Santen Pharmaceutical Co., Ltd., grants and personal fees from Otsuka Pharmaceutical Co., Ltd., grants and personal fees from Wakamoto Pharmaceutical Co., Ltd., grants from ROHTO Pharmaceutical Co., Ltd., grants from R-Tech Ueno, personal fees from Laboratoires Thea, grants from Alcon Japan, investor of Tear Solutions, grants and investor of Tsubota Laboratory, Inc., outside the submitted work.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.